MTPH.L Regulatory News (MTPH)

1 April 2015

Midatech Pharma PLC

("Midatech", the "Company" or the "Group")

Board Change

Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical with a diversified portfolio of high-value assets, today announces that Jeff Brown is stepping down from the Board of Directors post the IPO to pursue other business interests, effective of 30 April 2015.

Commenting on the Board change, Rolf Stahel, Non-executive Chairman of Midatech Pharma, said: "Jeff's counsel and guidance to Midatech up to and through our recent IPO has been a strong contributor to our success. His retirement from our Board is a natural transition as we continue to mature as a public company. We thank him for his valuable contribution and wish him the very best of luck in his future endeavours."

For more information, please contact:

Midatech Pharma plc

Jim Phillips, Chief Executive Officer

Tel: +44 (0)1235 841575

www.midatechpharma.com

Consilium Strategic Communications

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

midatech@consilium-comms.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Tel: +44 (0)20 7886 2500

Corporate Finance

Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith

Broking

Tom Salvesen

About Midatech Pharma PLC

Midatech Pharma is a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs. The Group has a strong pipeline of product candidates in clinical and pre-clinical development with a clear focus on the key therapeutic areas of diabetes, cancer and neurological/ophthalmological diseases.

Right place. Right time. Central to Midatech's business are two platform technologies that are designed to enable the targeted delivery and controlled release of existing drugs. Midatech's core platform is a pioneering drug conjugate delivery system based on gold-nanoparticles (GNPs) combined with existing drugs for targeted release at specific organs, cells or sites of disease. The Group's secondary platform (acquired through the acquisition of Q Chip in 2014) involves the consistent and precise encapsulation of active drug compounds within polymer microspheres that are designed to release the drug into the body in a highly controlled manner over a prolonged period of time.

The Group has collaborations with a number of speciality and major pharmaceutical companies and academic institutions to develop its platform technologies across a broad range of programmes within Midatech's priority therapeutic areas. The business strategy is to expedite the pipeline developments into revenue opportunities.

Midatech operates an in-house state-of-the-art nanoparticle manufacturing facility, based in Bilbao, Spain. The site has capacity for manufacturing sufficient materials for clinical trials and is fully licensed by the Spanish Medicines Agency for European compliance.

The Group is headquartered in Oxford, UK and employs 53 staff including 14 in Oxford, UK, 17 in Cardiff, UK and 18 in Bilbao, Spain. Across the Group there are 32 qualified scientists. For further company information see: www.midatechgroup.com.